ARTIDIS Device for Pancreatic Cancer
(ANoPs Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy.
The main questions this study aims to answer are:
* Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer?
* How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment?
This is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance.
Participants will:
* Undergo a standard-of-care pancreatic biopsy or surgical procedure
* Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device
* Continue to receive standard treatment and care, which is not influenced by the study
* Have clinical data, imaging results, and treatment outcomes collected
* Be followed every 3 months for up to 2 years
The study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Biopsy and Initial Assessment
Participants undergo a standard-of-care pancreatic biopsy or surgical procedure and provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device.
Follow-up
Participants are monitored every 3 months for up to 2 years to collect clinical data, imaging results, and treatment outcomes.
What Are the Treatments Tested in This Trial?
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants with suspected pancreatic cancer undergoing standard-of-care biopsy or surgery, with additional tissue measurement using the ARTIDIS ART-1 device and prospective collection of clinical outcomes.
Find a Clinic Near You
Who Is Running the Clinical Trial?
ARTIDIS AG
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.